Drug
Apabetalone
Apabetalone is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(17%)
Results Posted
50%(1 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_1
1
17%
Ph early_phase_1
1
17%
Ph phase_2
3
50%
Ph phase_3
1
17%
Phase Distribution
2
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(2)
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
Not yet recruiting1
unknown1
Recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
66.7%
Most Advanced
Phase 3
Trials by Phase
Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 31 (16.7%)
Trials by Status
not_yet_recruiting117%
completed233%
unknown117%
recruiting117%
terminated117%
Recent Activity
1 active trials
Showing 5 of 6
recruitingphase_2
A Study of Apabetalone in Subjects With Long -COVID
NCT06590324
terminatedphase_2
An Open-Label Study of Apabetalone in Covid Infection
NCT04894266
not_yet_recruitingphase_1
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
NCT03160430
unknownphase_2
Apabetalone for Pulmonary Arterial Hypertension
NCT04915300
completedearly_phase_1
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
NCT03655704
Clinical Trials (6)
Showing 6 of 6 trials
NCT06590324Phase 2
A Study of Apabetalone in Subjects With Long -COVID
NCT04894266Phase 2
An Open-Label Study of Apabetalone in Covid Infection
NCT03160430Phase 1
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
NCT04915300Phase 2
Apabetalone for Pulmonary Arterial Hypertension
NCT03655704Early Phase 1
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
NCT02586155Phase 3
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6